Cagrilintide
A compound that copies some actions of amylin, a hormone involved in appetite and blood sugar. It has been studied in human trials.
Whole vial: 5 mg Vial math ↓
Why people look it up
Cagrilintide attracts attention because researchers are testing whether an amylin-like signal can reduce appetite and body weight.
Body-weight reductionHUMAN CLINICAL EVIDENCE
A phase 2 randomized human trial measured weight loss with cagrilintide. Read source ↗
Appetite and fullnessMECHANISTIC / LAB EVIDENCE
Cagrilintide is an amylin analogue, which is why fullness is discussed. The cited phase 2 summary reports weight outcomes, not a directly measured fullness benefit. Read source ↗
Results attributed to CagriSemaINSUFFICIENT EVIDENCE
A cagrilintide-plus-semaglutide result cannot be credited to cagrilintide alone. Read source ↗
The labels show the evidence for each claim. Open a row for its source.
Dosage at a glance
Dosage source summary
- Lower trial groups
- 0.3 or 0.6 mg
- Middle trial group
- 1.2 mg
- Higher trial groups
- 2.4 or 4.5 mg
- How often
- Once weekly in the 2021 phase 2 trial
- Time on / time off
- 26-week study; not a community cycle.
- Route
- Subcutaneous trial product.
These are separate dose-finding groups, not an escalation sequence for a research vial.
These source amounts do not establish a safe human dose for a research vial.
Sources & individual reports
These are separate dose-finding groups, not an escalation sequence for a research vial. Source check: 2026-10-18.
Source coverage: 1 reviewed public account. Not a community consensus.
Report 1 ↗First-person account
- Amount reported
- 0.25 mg cagrilintide once, while also using 10 mg tirzepatide on a different day
- How often reported
- one cagrilintide administration reported; ongoing frequency not established
- Reported duration / cycle
- first week at the time of the comment
- Route (how it was taken)
- not stated
What the account says: Commenter reported appetite suppression after a first cagrilintide administration while also using tirzepatide. The effect cannot be assigned to cagrilintide alone.
Product match & source details
Product match: Combination use; exact research vial and formulation were not verified.
r/Peptidesource firsthand comment · Posted: 2025-07-30 · Reviewed: 2026-10-03.
How much agreement is there? Only one directly checked account is shown. This is separate from the randomized trial groups.
Public sources last reviewed: 2026-10-03. Product identity and reported results were not independently verified. Source method →
Evidence, sources & vial math
What the research actually showsHuman studies, evidence limits and mechanisms
What has actually been studied?
A randomized phase 2 trial in adults with overweight or obesity found weight loss with the studied cagrilintide product. Results for a combination with semaglutide are a separate question.
Evidence limits: Trial results do not establish the identity, preparation, or safety of this separately sold research vial. Long-term outcomes require product-specific study.
Product status: Research-vial listings are not FDA-approved medicines. Approved-use labels on this page refer only to the named finished prescription product.
Human research
Cagrilintide dose-finding phase 2 trial 2021
What was found: All studied cagrilintide groups had greater mean weight reduction than pooled placebo.
Main limit: Trial groups and studied formulation; dose escalation and adverse events require full-paper context. Not a regimen for this vial.
Study setup and amounts
- Who
- Adults with overweight or obesity, without diabetes
- Number of participants
- 706 randomized across all trial groups
- Study design
- Randomized, double-blind, placebo- and active-controlled phase 2 trial
- Route
- Subcutaneous
- Amount studied
- Separate 0.3, 0.6, 1.2, 2.4, and 4.5 mg groups
- Frequency
- Once weekly
- Duration
- 26 treatment weeks
- Outcome measured
- Percentage change in body weight
Study and prescription-product amounts describe those sources. They do not select an amount for an online research vial.
How researchers think it might work
Cagrilintide is a long-acting version of amylin, a hormone involved in feeling full.
Show scientific explanation
The cited phase 2 study describes an amylin analogue tested in once-weekly study groups for body-weight outcomes. Read supporting source ↗
Vial & syringe mathTurn the vial total and liquid volume into concentration and syringe units
Vial & syringe math
Change the vial total and final liquid volume to see what each U-100 syringe mark represents.
The starting 1 mL is a math example. Enter your final mixed volume to update the numbers.
100 U-100 syringe units = 1 mL. These results assume the labeled amount is evenly mixed through the final liquid volume.
See source amounts as syringe units
Human trial groups. These are separate study groups, not a sequence to follow. Trial results concern the studied formulation, not this research vial. Read the Cagrilintide phase 2 dose-finding trial (2021) ↗
| Source row | Amount | Liquid volume | U-100 units | Full amounts in one vial* |
|---|---|---|---|---|
| Trial group | 300 mcg (0.3 mg) | — | — | — |
| Trial group | 600 mcg (0.6 mg) | — | — | — |
| Trial group | 1.2 mg | — | — | — |
| Trial group | 2.4 mg | — | — | — |
| Trial group | 4.5 mg | — | — | — |
*Whole amounts by mass, before handling loss. Flags identify amounts above the vial total, volumes above the 100-unit scale, or measurements below one unit. Source amounts describe the named product or study; they do not choose an amount for a research vial.
About this listingResearch-use-only status, seller names and additional background
A research material is not intended for human use. Its name or lab report does not establish suitability for a person. What research use only means →
Compiled by PeptideWhy · Scientific sources last checked 2026-10-03 · Editorial policy · Corrections